论文部分内容阅读
目的:分析头孢哌酮/舒巴坦引起不良反应(ADR)的特点,为临床合理使用提供参考。方法:对我院2006～2009年上报的头孢哌酮/舒巴坦ADR 84例进行统计分析。结果:ADR表现主要为皮肤及其附属系统(81.61%),其次为全身性损害(10.34%),程度主要为轻至中度的一般ADR(95.24%)。结论:临床应重视头孢哌酮/舒巴坦引起的ADR,结合ADR发生特点做好ADR的预防与处理,加强儿童和老年人合理使用,保障患者用药安全。
Objective: To analyze the characteristics of cefoperazone / sulbactam-induced adverse reactions (ADRs) and provide references for clinical rational use. Methods: A total of 84 cases of cefoperazone / sulbactam ADR reported in our hospital from 2006 to 2009 were analyzed statistically. Results: The main manifestations of ADR were skin and its accessory system (81.61%), followed by systemic injury (10.34%), and mild to moderate general ADR (95.24%). Conclusions: Clinical should pay more attention to the ADR caused by cefoperazone / sulbactam and combine the features of ADR with the prevention and treatment of ADR, enhance the rational use of children and the elderly, and ensure the safety of patients.